Overview

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Status:
RECRUITING
Trial end date:
2029-03-19
Target enrollment:
Participant gender:
Summary
A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.
Phase:
PHASE2
Details
Lead Sponsor:
Tetraphase Pharmaceuticals, Inc
Collaborator:
Innoviva Specialty Therapeutics
Treatments:
eravacycline